Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
246
Recruiting, any sponsor type, condition "heart failure"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting246
- Completed1,188
246 trials
Showing 1 to 25, recently updated first.
- A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and ChemotherapyPivotal-lookingRecruiting
Pierre Fabre MedicamentIndustry
NCT03394365 · 115 participants (planned) · Start Dec 29, 2017 · Primary completion May 31, 2030
Drug: tabelecleucel · For: Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD); Solid Organ Transplant Complications; Lymphoproliferative Disorders and 2 more
Sites: Duarte, California; La Jolla, California; Loma Linda, California · 72 sites in all
- Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection FractionPivotal-lookingRecruiting
CytokineticsIndustry
NCT06736574 · 1,800 participants (planned) · Start Dec 19, 2024 · Primary completion Sep 2027
Drug: Omecamtiv Mecarbil (OM); Placebo · For: Heart Failure; Heart Failure With Reduced Ejection Fraction
Sites: Alexander City, Alabama; Birmingham, Alabama; Tucson, Arizona · 215 sites in all
National Heart Centre SingaporeAcademic, hospital or other
NCT06645691 · 200 participants (planned) · Start Oct 17, 2024 · Primary completion May 31, 2028
Drug: Hyperpolarized 13C-pyruvate · For: Heart Failure; Cardiometabolic Syndrome; Cancer Diagnosis and 2 more
Sites: Singapore, Singapore
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)Industry
NCT06965621 · 20 participants (planned) · Start Nov 5, 2025 · Primary completion Mar 30, 2027
Drug: 18F-metaFluorobenzylguanidine; Rubidium-82 · For: Heart Failure; Ischemic Cardiomyopathy; ICD Patients
Sites: Houston, Texas
VA Office of Research and DevelopmentFederal agency
NCT06312748 · 90 participants (planned) · Start May 19, 2021 · Primary completion Sep 30, 2028
Drug: L-Citrulline; Placebo for L-Citrulline and 4 more · For: Heart Failure With Preserved Ejection Fraction; Inflammation
Sites: Salt Lake City, Utah
- Cardiogenic Shock Working Group RegistryRecruiting
Tufts Medical CenterAcademic, hospital or other
NCT04682483 · 20,000 participants (planned) · Start Dec 4, 2017 · Primary completion Dec 2027
Drug: Vasopressor; Inotrope · For: Cardiogenic Shock
Sites: Weston, Florida; Chicago, Illinois; Indianapolis, Indiana · 22 sites in all
- CRF2 Agonist for the Treatment of Worsening Heart FailurePivotal-lookingRecruiting
Corteria PharmaceuticalsIndustry
NCT06815471 · 210 participants (planned) · Start Aug 7, 2025 · Primary completion Jul 2027
Drug: COR-1167; Placebo · For: Worsening Heart Failure
Sites: Indianapolis, Indiana; Detroit, Michigan; Greensboro, North Carolina · 55 sites in all
University of AarhusAcademic, hospital or other
NCT05834803 · 80 participants (planned) · Start Jun 26, 2023 · Primary completion Jun 1, 2027
Drug: Optimal medical therapy (OMT) · For: Renovascular Hypertension; Renovascular Hypertension With Renal Failure; Heart Failure and 1 more
Sites: Aarhus N, Denmark; Copenhagen, Denmark; Odense C, Denmark
- CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With ColchicinePivotal-lookingRecruiting
Niguarda HospitalAcademic, hospital or other
NCT06158698 · 80 participants (planned) · Start Nov 14, 2023 · Primary completion Mar 2, 2029
Drug: Colchicine · For: Cardiomyopathies; Myocarditis; Inflammatory Cardiomyopathy and 2 more
Sites: Naples, Italy; Bologna, Italy; Trieste, Italy · 12 sites in all
- Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05714085 · 342 participants (planned) · Start May 31, 2023 · Primary completion Aug 20, 2029
Drug: Vericiguat tablet; Vericiguat suspension and 2 more · For: Heart Failure; Left Ventricular Systolic Dysfunction
Sites: Los Angeles, California; Palo Alto, California; San Bernardino, California · 112 sites in all
- A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart FailurePivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06424288 · 6,712 participants (planned) · Start Jun 17, 2024 · Primary completion May 22, 2028
Drug: vicadrostat; empagliflozin and 1 more · For: Heart Failure
Sites: Mobile, Alabama; Chula Vista, California; Orange, California · 672 sites in all
- A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious InfectionsPivotal-lookingRecruiting
X4 PharmaceuticalsIndustry
NCT06056297 · 176 participants (planned) · Start Jun 6, 2024 · Primary completion Sep 2027
Drug: Mavorixafor; Placebo · For: Neutropenia
Sites: Phoenix, Arizona; Irvine, California; La Jolla, California · 115 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT07465653 · 12 participants (planned) · Start Mar 18, 2026 · Primary completion Dec 8, 2026
Drug: HJB647 low dose; HJB647 high dose · For: Heart Failure With Reduced Ejection Fraction
Sites: Bradenton, Florida; Inverness, Florida; Jacksonville, Florida · 7 sites in all
- A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the HeartPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06935370 · 4,200 participants (planned) · Start May 20, 2025 · Primary completion Feb 4, 2029
Drug: vicadrostat; empagliflozin and 1 more · For: Heart Failure
Sites: Beverly Hills, California; Covina, California; Encinitas, California · 596 sites in all
Sinotau Pharmaceutical GroupIndustry
NCT07443696 · 40 participants (planned) · Start Dec 18, 2025 · Primary completion Dec 31, 2026
Drug: Fasting XTR003/¹⁸F-FDG PET myocardial metabolic imaging; Glucose-loaded ¹⁸F-FDG PET Myocardial Metabolic Imaging · For: Ischemic Cardiomyopathy; Heart Failure
Sites: Beijing, China; Tianjin, China · 3 sites in all
- A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart FailurePivotal-lookingRecruiting
AnaCardio ABIndustry
NCT07584967 · 400 participants (planned) · Start Nov 15, 2026 · Primary completion Jul 30, 2028
Drug: AC01 · For: Heart Failure With Reduced Ejection Fraction (HFrEF)
Sites: Van Nuys, California; Crystal River, Florida; Schaumburg, Illinois · 14 sites in all
Madrigal Pharmaceuticals, Inc.Industry
NCT07830758 · 90 participants (planned) · Start Oct 16, 2026 · Primary completion Nov 2027
Drug: Resmetirom; Placebo · For: MASH - Metabolic Dysfunction-Associated Steatohepatitis; Heart Failure With Preserved Ejection Fraction (HFPEF)
Sites: Peoria, Arizona; Oxnard, California; Fort Myers, Florida · 5 sites in all
Nagoya UniversityAcademic, hospital or other
NCT07855692 · 90 participants (planned) · Start Nov 5, 2026 · Primary completion May 31, 2029
Drug: Tamibarotene; Placebo · For: HFpEF - Heart Failure With Preserved Ejection Fraction
Sites: Nagoya, Japan; Ōbu, Japan; Tsu, Japan · 4 sites in all
Montreal Heart InstituteAcademic, hospital or other
NCT06217120 · 64 participants (planned) · Start Nov 6, 2026 · Primary completion Apr 2027
Drug: Colchicine; Placebo · For: Heart Failure With Preserved Ejection Fraction; Microvascular Coronary Artery Disease
Sites: Montreal, Canada
- The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of LifePivotal-lookingRecruiting
China-Japan Friendship HospitalAcademic, hospital or other
NCT05991128 · 170 participants (planned) · Start Aug 1, 2023 · Primary completion Aug 1, 2027
Drug: Ferric derisomaltose; Placebo · For: Heart Failure With Preserved Ejection Fraction; Iron Deficiencies; Acute Heart Failure
Sites: Beijing, China
- The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)Pivotal-lookingRecruiting
China-Japan Friendship HospitalAcademic, hospital or other
NCT05971732 · 146 participants (planned) · Start Aug 1, 2023 · Primary completion Aug 1, 2027
Drug: Ferric derisomaltose; Placebo · For: Heart Failure With Reduced Ejection Fraction; Iron Deficiency; Acute Heart Failure
Sites: Beijing, China
- SHengXIaN-QuYu DEcoction in Heart Failure With Reduced and Mildly Reduced Ejection FractionPivotal-lookingRecruiting
China-Japan Friendship HospitalAcademic, hospital or other
NCT05583773 · 336 participants (planned) · Start Mar 29, 2023 · Primary completion Mar 31, 2027
Drug: ShengXian-QuYu Decoction · For: Heart Failure
Sites: Beijing, China; Baoding, China; Qinhuangdao, China · 26 sites in all
- The Effects of Low-Dose Versus High-Dose Intravenous IRON Therapy With Ferric DerisomaltOSE in Patients With Chronic Heart Failure and Iron DeficiencyPivotal-lookingRecruiting
China-Japan Friendship HospitalAcademic, hospital or other
NCT06427343 · 114 participants (planned) · Start Oct 1, 2023 · Primary completion Aug 1, 2027
Drug: High-dose ferric derisomaltose; Low-dose ferric derisomaltose · For: Heart Failure; Iron Deficiency
Sites: Beijing, China
- SWITCH: Apixaban vs Vitamin K in HM3Pivotal-lookingRecruiting
Columbia UniversityAcademic, hospital or other
NCT07471139 · 460 participants (planned) · Start Oct 15, 2026 · Primary completion Aug 2029
Drug: Warfarin; Apixaban · For: LVAD (Left Ventricular Assist Device) Thrombosis; Heart Failure; Bleeding and 3 more
Sites: New York, New York
- Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart FailurePivotal-lookingRecruiting
Christian SchulzeAcademic, hospital or other
NCT07038356 · 536 participants (planned) · Start Dec 8, 2025 · Primary completion Apr 30, 2027
Drug: Empagliflozin 10 MG Oral Tablet [Jardiance]; Placebo · For: Acute Decompensated Heart Failure (ADHF)
Sites: Jena, Germany; Bad Nauheim, Germany; Berlin, Germany · 12 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.